Easterly Investment Partners’s Collegium Pharmaceutical COLL Stock Holding History

Easterly Investment Partners’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Buy	44,231 +7,000	+19%	+$239K	0.08%	167
2026 Q1	$1.22M	Buy	37,231 +2,100	+6%	+$88.9K	0.09%	109
2025 Q4	$1.63M	Sell	35,131 -16,281	-32%	-$681K	0.1%	133
2025 Q3	$1.8M	Sell	51,412 -1,000	-2%	-$34.8K	0.12%	123
2025 Q2	$1.55M	Sell	52,412 -3,746	-7%	-$107K	0.11%	126
2025 Q1	$1.68M	Hold	56,158	–	–	0.14%	119
2024 Q4	$1.61M	Hold	56,158	–	–	0.13%	128
2024 Q3	$2.17M	Buy	56,158 +13,529	+32%	+$482K	0.17%	108
2024 Q2	$1.37M	Sell	42,629 -7,000	-14%	-$243K	0.12%	133
2024 Q1	$1.93M	Sell	49,629 -22	-0%	-$770	0.15%	123
2023 Q4	$1.53M	Hold	49,651	–	–	0.16%	121
2023 Q3	$1.11M	Hold	49,651	–	–	0.12%	129
2023 Q2	$1.07M	Buy	49,651 +24,622	+98%	+$559K	0.09%	140
2023 Q1	$600K	Buy	25,029 +3,000	+14%	+$79.6K	0.05%	155
2022 Q4	$511K	Hold	22,029	–	–	0.04%	155
2022 Q3	$353K	Hold	22,029	–	–	0.03%	164
2022 Q2	$390K	Sell	22,029 -2,000	-8%	-$33.6K	0.03%	159
2022 Q1	$489K	Buy	+24,029	New	+$454K	0.04%	162

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Easterly Investment Partners's COLL Position: Q2 2026 in Review

Easterly Investment Partners increased its Collegium Pharmaceutical (COLL) stake by 19% in Q2 2026, buying an estimated $239K and bringing the position to 44,231 shares worth $1.6M. The position accounts for 0.08% of the portfolio, ranked #167.

Easterly Investment Partners first reported a position in COLL in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.17M in Q3 2024. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

Easterly Investment Partners held 44,231 shares of Collegium Pharmaceutical worth $1.6M as of Q2 2026.
Easterly Investment Partners bought 7,000 Collegium Pharmaceutical shares in Q2 2026, an estimated $239K.
Collegium Pharmaceutical made up 0.08% of Easterly Investment Partners's portfolio in Q2 2026, its #167 holding.
Easterly Investment Partners first reported a position in Collegium Pharmaceutical in Q1 2022 and has held it in 18 quarters since.
Easterly Investment Partners's Collegium Pharmaceutical position peaked at $2.17M in Q3 2024.
279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Easterly Investment Partners's 13F filing for Q2 2026, filed 23 Jul 2026.